Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR WAIVER OF RULE BY SPECIAL AUTHORITY

Form SA1683 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Azithromycin		
Initial application — bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections Applications only from a relevant specialist. Approvals valid without further renewal unless notified. Prerequisites(tick boxes where appropriate)		
Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*		
Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*		
or Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms* or		
Patient has an atypical Mycobacterium infection		
Note: Indications marked with * are unapproved indications.		
Initial application — non-cystic fibrosis bronchiectasis* Applications only from a respiratory specialist or paediatrician. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)		
For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*		
Patient is aged 18 and under		
Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period or		
Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period		
Note: Indications marked with * are unapproved indications.		
Renewal — non-cystic fibrosis bronchiectasis*		
Current approval Number (if known):		
Applications only from a respiratory specialist or paediatrician. Approvals valid for 12 months. The patient must not have had more than 1 prior approval. Prerequisites(tick boxes where appropriate)		
The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis and		
Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment and		
	nan a total of 24 months' azithromycin cumulative trea	atment (see note)
Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications		

I confirm the above details are correct and that in signing this form I understand I may be audited.